Message from the Chair – This New Year brings great anticipation for progress in the treatment of melanoma and skin cancers, like cutaneous squamous cell carcinoma (cSCC). We have been anxiously awaiting provincial listings for adjuvant therapies for melanoma – in particular the adjuvant (for stage III fully resected patients), targeted therapy combination of Dabrafenib and Trametinib, and the adjuvant immunotherapies – Pembrolizumab and Nivolumab.

Message from the Chair – This New Year brings great anticipation for progress in the treatment of melanoma and skin cancers, like cutaneous squamous cell carcinoma (cSCC). We have been anxiously awaiting provincial listings for adjuvant therapies for melanoma – in particular the adjuvant (for stage III fully resected patients), targeted therapy combination of Dabrafenib and Trametinib, and the adjuvant immunotherapies – Pembrolizumab and Nivolumab.